Bend, OR, USA, November 29, 2021 — The newly formed company, Phoenix-Micron, Inc., announced today it has completed the spin-out of the Phoenix MICRON® imaging platform from Phoenix Technology Group. This move is designed to increase focus and innovation in products designed to serve the eye and eye-brain research community. The new company, Phoenix-Micron, Inc.
Age-related macular degeneration affects tens of millions of people worldwide, leading to vision impairment and blindness. Anti-VEGF treatment helps only 25-40% of patients, leaving others with no recourse to this progressive blinding disease. In their article, “Suppression of aberrant choroidal neovascularization through activation of the aryl hydrocarbon receptor,” Choudhary et al explore potential treatment using
Hint: It Starts with the Animal Angle During our hands-on training, we review animal positioning until every user is completely comfortable. But like most other lab equipment task, it does take some practice. Aligning the animal just right can be the difference between a great and a good fundus image. We’ve put together a
The most common cause of blindness in developed societies, age-related macular degeneration (AMD) robs the victim of the crucially important focused macular vision. While still devastating, wet AMD has a robust mouse model and the treatment option of anti-vascular endothelial growth factor (VEGF) subretinal injections. The Phoenix MICRON® laser allows precise delivery of 532 nm
Another ARVO passed by in a blur of research, scientific discussions, and seeing science friends. If you came by our booth, thank you for swinging by to chat with the Phoenix team. If you didn’t get a chance, please let me know if you have any questions about the Micron system and look for our